Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
CRSP
CRISPR Therapeutics
$64.52
Login to display CRISPR Therapeutics (CRSP) recommendation from the last 90 days from financial news and social media. Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Outperform the market
Chart
$52.98 (+21.78%)
$54.82 (+17.69%)
$36.14 (+78.53%)
$47.83 (+34.89%)
CRSP has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
High volatilty
CRSP overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
CRSP Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CRSP Street view is bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayCRSP Earnings
The TTM reflects 12-month period, providing review of CRSP financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
AMGN
282.90
+3.13%
VCEL
31.40
-1.23%
NBIX
141.61
+0.96%
IBRX
2.46
-4.47%
GILD
111.58
-0.89%
What is CRSP current stock price?
What are CRSP stock strengths?
What risks are associated with CRSP stock?
When is CRSP next earnings report?
What is CRSP market cap and volume?
What is CRSP's current Stock IQ?
Should I buy CRSP stock right now?
Is CRSP a Strong Buy right now?
What does a 'Strong Buy' rating mean for CRSP?
What does a 'Strong Sell' rating mean for CRSP?
What factors influence CRSP's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
CRSP
CRISPR Therapeutics
Current Price
$64.52
Stock Insights
Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Outperform the market
Linked to CRSP
AMGN
282.90
+3.13%
VCEL
31.40
-1.23%
NBIX
141.61
+0.96%
IBRX
2.46
-4.47%
GILD
111.58
-0.89%
Login to view CRISPR Therapeutics (CRSP) recommendation from the last 90 days from financial news and social media.
Chart
$52.98 (+21.78%)
$54.82 (+17.69%)
$36.14 (+78.53%)
$47.83 (+34.89%)
CRSP Analysts Opinion
CRSP Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Outperform the market
CRSP Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CRSP Street view is bullish and have positive views on the near-term outlook
CRSP has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
High volatilty
Average key support and resistance price levels.
Login to displayCRSP Earnings
The TTM data reflects the most recent 12-month period, providing overview of CRSP financial performance.
CRSP Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
CRSP Latest Analysis
Could This Beaten-Down Stock Help You Become a Millionaire?. Key PointsCRISPR Therapeutics has a couple of pipeline candidates with massive opportunities.
Today
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Heres Why. In the latest trading session CRISPR Therapeutics AG (CRSP) closed at $61.67 marking a 2.24% move from the previous day.
Fri Sep 26, 2025
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy. CAMBRIDGE Mass. Sept. 25 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics Inc. (NASDAQ:NTLA) a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies today announced longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex
Thu Sep 25, 2025
Notable Friday Option Activity: CRSP CALM ABNB. Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in CRISPR Therapeutics AG (Symbol: CRSP) where a total of 10666 contracts have traded so far representing approximately 1.1 million underlying shares. That amounts to ab
Fri Sep 19, 2025
JP Morgan Initiates Coverage of CRISPR Therapeutics (CRSP) with Overweight Recommendation. Fintel reports that on September 18 2025 JP Morgan initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Overweight recommendation.
Thu Sep 18, 2025
CRISPR Therapeutics wins new Overweight rating at J.P. Morgan on pipeline prospects.
Thu Sep 18, 2025
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises. MarketNewsUpdates News Commentary from BioSpace the global size was Avant Technologies Inc. (OTCQB:) Tempus AI Inc. (NASDAQ:) CRISPR Therapeutics (NASDAQ:) BioNTech SE (NASDAQ:) Bristol Myers Squibb Company (NYSE:). The report said: ".Major Trends in the Cell Therapy Market Are: Demand for Regenerative Medicine: Patients with untreated illnesses and due to its ability to restore the f
Thu Sep 18, 2025
Crispr Therapeutics: Why Stock Fell On Q2 Earnings And Why Were Now Back On Track.
Wed Sep 17, 2025
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?. Based on the average brokerage recommendation (ABR) CRISPR Therapeutics (CRSP) should be added to ones portfolio. Wall Street analysts overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So is the stock worth buying?
Thu Sep 11, 2025
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade. In the most recent trading session CRISPR Therapeutics AG (CRSP) closed at $51.81 indicating a -3.5% shift from the previous trading day.
Wed Sep 10, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CRSP Stock trends
CRSP Stock performance
CRSP Stock analysis
CRSP investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings